Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells

Sunil K Halder, Kevin G Osteen, Ayman Al-Hendy, Sunil K Halder, Kevin G Osteen, Ayman Al-Hendy

Abstract

Study question: Can biologically active vitamin D3 [1,25(OH)₂D3] regulate the expression and activity of matrix metalloproteinases (MMPs) in human uterine fibroid cells?

Summary answer: 1,25(OH)₂D3 effectively reduced the expression and activities of MMP-2 and MMP-9 in cultured human uterine fibroid cells.

What is known already: Uterine fibroids (leiomyoma) express higher levels of MMP activity than adjacent normal myometrium, and this is associated with uterine fibroid pathogenesis. However, it is unknown whether 1,25(OH)₂D3 can regulate the expression and activities of MMPs in human uterine fibroid cells.

Study design, size, duration: Surgically removed fresh fibroid tissue was used to generate primary uterine fibroid cells.

Participants/materials, setting, methods: An immortalized human uterine fibroid cell line (HuLM) and/or primary human uterine fibroid cells isolated from fresh fibroid tissue were used to examine the expression of several MMPs, tissue inhibitors of metalloproteinases (TIMP) 1 and 2 and the activities of MMP-2 and MMP-9 after 1,25(OH)₂D3 treatment. Real-time PCR and western blots analyses were used to measure mRNA and protein expression of MMPs, respectively. Supernatant cell culture media were analyzed for MMP-2 and MMP-9 activities using a gelatin zymography assay.

Main results and the role of chance: 1-1000 nM 1,25(OH)₂D3 significantly reduced mRNA levels of MMP-2 and MMP-9 in HuLM cells in a concentration-dependent manner (P < 0.5 to P < 0.001). The mRNA levels of MMP-1, MMP-3, MMP-13 and MMP-14 in HuLM cells were also reduced by 1,25(OH)₂D3. 1,25(OH)₂D3 significantly reduced MMP-2 and MMP-9 protein levels in a concentration-dependent manner in both HuLM and primary uterine fibroid cells (P < 0.05 to P < 0.001). Moreover, 1,25(OH)₂D3 increased the mRNA levels of vitamin D receptor (VDR) and TIMP-2 in a concentration-dependent manner in HuLM cells (P < 0.05 to P < 0.01). 1,25(OH)₂D3 also significantly increased protein levels of VDR and TIMP-2 in all cell types tested (P < 0.05 to P < 0.001). Gelatin zymography revealed that pro-MMP-2, active MMP-2 and pro-MMP-9 were down-regulated by 1,25(OH)₂D3 in a concentration-dependent manner; however, the active MMP-9 was undetectable.

Limitations, reasons for caution: This study was performed using in vitro uterine fibroid cell cultures and the results were extrapolated to in vivo situation of uterine fibroids. Moreover, in this study the interaction of vitamin D3 with other regulators such as steroid hormone receptors was not explored.

Wider implications of the findings: This study reveals an important biological function of 1,25(OH)₂D3 in the regulation of expression and activities of MMP-2 and MMP-9. Thus, 1,25(OH)₂D3 might be a potential effective, safe non-surgical treatment option for human uterine fibroids.

Keywords: MMPs; TIMP-2; VDR; fibroids; vitamin D3.

Figures

Figure 1
Figure 1
Effect of 1,25(OH)2D3 on mRNA expression of MMPs in cultured immortalized human uterine fibroid (HuLM) cells. Total RNA was isolated from HuLM cells treated with increasing concentrations of 1,25(OH)2D3 (0, 1, 10, 100 and 1000 nM) for 48 h. Equal amounts of each total RNA was used to perform quantitative real-time PCR analyses as indicated. Total RNA (1 µg) was reverse transcribed to cDNA and then real-time PCR analyses were performed for MMP-2 (A) and MMP-9 (B), MMP-1 (C), MMP-3 (D), MMP-13 (E) and MMP-14 (F) using gene-specific forward and reverse primers as described in the section Materials and Methods. The mRNA expression levels of above MMPs were normalized with GAPDH (internal control) and the normalized values were used to generate the graphs. Data are means ± SEM, *P < 0.05, **P < 0.01 and ***P < 0.001 when compared with corresponding untreated control (0). §§P < 0.01 when compared between 1,25(OH)2D3-treated data points. These experiments were repeated twice with similar results.
Figure 2
Figure 2
Effect of 1,25(OH)2D3 on mRNA expressions of the VDR and TIMP 1 and 2 in cultured immortalized human uterine fibroid (HuLM) cells. Real-time PCR analyses for mRNA expressions of VDR, TIMP-1 and TIMP-2 were performed using gene-specific sense and anti-sense primers as described in the section Materials and methods. The mRNA expression levels of VDR, TIMP-1 and TIMP-2 were normalized with GAPDH and the normalized values were used to generate the graphs. Data are means ± SEM, n = 3, **P < 0.01 when compared with corresponding untreated control. §P < 0.05 when compared between 1,25(OH)2D3-treated data points. This experiment was repeated twice with similar results.
Figure 3
Figure 3
Effect of 1,25(OH)2D3 on protein expression of MMP 2 and 9 in cultured human uterine fibroid cells. Immortalized human uterine fibroid (HuLM) cells (A) and primary uterine fibroid cells (B) were serum starved and treated with increasing concentrations of 1,25(OH)2D3 (0, 1, 10, 100 and 1000 nM) for 48 h. For each condition, an equal amount of protein lysate was analyzed by western blotting with anti-MMP-2 and anti-MMP-9 antibodies. Western blot with anti-β-actin antibody was used as the loading control. The intensity of each protein band was quantified and normalized with corresponding β-actin, and the normalized values were used to generate the graphs. Data are the mean ± SEM, n = 3, *P < 0.05, **P < 0.01 and ***P < 0.001 when compared with corresponding untreated control. §§P < 0.01 and §§§P < 0.001 when compared between 1,25(OH)2D3-treated data points. This experiment was repeated twice with similar results.
Figure 4
Figure 4
Effect of 1,25(OH)2D3 on protein expression of VDR in cultured human uterine fibroid cells. Immortalized human uterine fibroid (HuLM) cells (A) and primary human uterine fibroid cells (B) were serum starved and treated with increasing concentrations of 1,25(OH)2D3 (0, 1, 10, 100 and 1000 nM) for 48 h. Equal amounts of each cell lysate were analyzed by western blotting using anti-VDR antibody. The intensity of each protein band was quantified and normalized with corresponding β-actin, and the normalized values were used to generate the graphs. *P < 0.05 and ***P < 0.001 when compared with corresponding untreated control. §§§P < 0.001 when compared between 1,25(OH)2D3-treated data points. This experiment was repeated twice with similar results.
Figure 5
Figure 5
Effect of 1,25(OH)2D3 on protein expression of TIMP-2 in cultured human uterine fibroid cells. Lysates from immortalized human uterine fibroid (HuLM) cells (A) and primary uterine fibroid cells (B) treated with increasing concentrations of 1,25(OH)2D3 (as described above) were analyzed by western blots using anti-TIMP-2 antibody. Western blot with the anti-β-actin antibody was used as the loading control. The intensity of each protein band was quantified and normalized with corresponding β-actin, and the normalized values were used to generate the graphs. Data are mean ± SEM, n = 3, *P < 0.05, **P < 0.01 and ***P < 0.001 when compared with corresponding untreated control. This experiment was repeated twice with similar results.
Figure 6
Figure 6
Effect of 1,25(OH)2D3 on gelatinolytic activities of MMP 2 and 9 in cultured human uterine fibroid cells. Both immortalized human uterine fibroid (HuLM) cells (A) and primary uterine fibroid cells (B) were serum starved and treated with increasing concentrations of 1,25(OH)2D3 (0, 1, 10, 100 M and 1000 nM) for 48 h. Each supernatant medium (40 µl/each sample) was analyzed in 7.5% SDS PAGE gelatin zymography as described in the section Materials and methods. The digestion of gelatin in the gel by MMP-2 and MMP-9 enzymes cause the negative (unstained) bands. The pro-MMP-2 (72 kDa) and active MMP-2 (65 kDa) digested bands were detected in the gels which were decreased by 1,25(OH)2D3. Similarly, the pro-MMP-9 (92 kDa) was also detected in supernatant media in both cell types, which were also decreased by 1,25(OH)2D3. The active form of MMP-9 was undetectable in supernatant media of both cell types. This experiment was repeated twice with similar results.

References

    1. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem. 1995;270:5872–5876.
    1. Allan JA, Docherty AJ, Barker PJ, Huskisson NS, Reynolds JJ, Murphy G. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J. 1995;309(Pt 1):299–306.
    1. Anand SP, Selvaraj P. Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis. Clin Immunol. 2009;133:126–131.
    1. Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology. 2003;14:247–250.
    1. Berto AG, Sampaio LO, Franco CR, Cesar RM, Jr, Michelacci YM. A comparative analysis of structure and spatial distribution of decorin in human leiomyoma and normal myometrium. Biochim Biophys Acta. 2003;1619:98–112.
    1. Blauer M, Rovio PH, Ylikomi T, Heinonen PK. Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro. Fertil Steril. 2009;91:1919–1925.
    1. Bogusiewicz M, Stryjecka-Zimmer M, Postawski K, Jakimiuk AJ, Rechberger T. Activity of matrix metalloproteinase-2 and -9 and contents of their tissue inhibitors in uterine leiomyoma and corresponding myometrium. Gynecol Endocrinol. 2007;23:541–546.
    1. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267–283.
    1. Butler GS, Will H, Atkinson SJ, Murphy G. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem. 1997;244:653–657.
    1. Byers PH. Collagens: building blocks at the end of the development line. Clin Genet. 2000;58:270–279.
    1. Carney SA, Tahara H, Swartz CD, Risinger JI, He H, Moore AB, Haseman JK, Barrett JC, Dixon D. Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest. 2002;82:719–728.
    1. Catherino WH, Leppert PC, Stenmark MH, Payson M, Potlog-Nahari C, Nieman LK, Segars JH. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer. 2004;40:204–217.
    1. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260–1270.
    1. Chang JC, Wysocki A, Tchou-Wong KM, Moskowitz N, Zhang Y, Rom WN. Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax. 1996;51:306–311.
    1. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25:99–113.
    1. Chung L, Dinakarpandian D, Yoshida N, Lauer-Fields JL, Fields GB, Visse R, Nagase H. Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J. 2004;23:3020–3030.
    1. Coussens A, Timms PM, Boucher BJ, Venton TR, Ashcroft AT, Skolimowska KH, Newton SM, Wilkinson KA, Davidson RN, Griffiths CJ, et al. 1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology. 2009;127:539–548.
    1. Dou Q, Tarnuzzer RW, Williams RS, Schultz GS, Chegini N. Differential expression of matrix metalloproteinases and their tissue inhibitors in leiomyomata: a mechanism for gonadotrophin releasing hormone agonist-induced tumour regression. Mol Hum Reprod. 1997;3:1005–1014.
    1. Farhi J, Ashkenazi J, Feldberg D, Dicker D, Orvieto R, Ben Rafael Z. Effect of uterine leiomyomata on the results of in-vitro fertilization treatment. Hum Reprod. 1995;10:2576–2578.
    1. Gelse K, Poschl E, Aigner T. Collagens—structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003;55:1531–1546.
    1. Gilad LA, Tirosh O, Schwartz B. Phytoestrogens regulate transcription and translation of vitamin D receptor in colon cancer cells. J Endocrinol. 2006;191:387–398.
    1. Gioia M, Monaco S, Fasciglione GF, Coletti A, Modesti A, Marini S, Coletta M. Characterization of the mechanisms by which gelatinase A, neutrophil collagenase, and membrane-type metalloproteinase MMP-14 recognize collagen I and enzymatically process the two alpha-chains. J Mol Biol. 2007;368:1101–1113.
    1. Halder SK, Beauchamp RD, Datta PK. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res. 2005;307:231–246.
    1. Halder SK, Goodwin JS, Al-Hendy A. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011;96:E754–E762.
    1. Halder SK, Sharan C, Al-Hendy A. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012;86:116.
    1. Hibbs MS, Hasty KA, Seyer JM, Kang AH, Mainardi CL. Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem. 1985;260:2493–2500.
    1. Holick MF. Vitamin D: a millennium perspective. J Cell Biochem. 2003;88:296–307.
    1. Inada M, Wang Y, Byrne MH, Rahman MU, Miyaura C, Lopez-Otin C, Krane SM. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci USA. 2004;101:17192–17197.
    1. Koli K, Keski-Oja J. 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000;11:221–229.
    1. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004;49:187–198.
    1. Leppert PC, Baginski T, Prupas C, Catherino WH, Pletcher S, Segars JH. Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. Fertil Steril. 2004;82:1182–1187.
    1. Leppert PC, Catherino WH, Segars JH. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol. 2006;195:415–420.
    1. Levens E, Luo X, Ding L, Williams RS, Chegini N. Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-beta through Smad and MAPK-mediated signalling. Mol Hum Reprod. 2005;11:489–494.
    1. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res. 2000;46:214–224.
    1. Li YY, Kadokami T, Wang P, McTiernan CF, Feldman AM. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol. 2002;282:H983–H989.
    1. Limper AH, Roman J. Fibronectin. A versatile matrix protein with roles in thoracic development, repair and infection. Chest. 1992;101:1663–1673.
    1. Malik M, Catherino WH. Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arrays. Fertil Steril. 2007;87:1166–1172.
    1. Malik M, Norian J, McCarthy-Keith D, Britten J, Catherino WH. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med. 2010;28:169–179.
    1. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays. 1992;14:455–463.
    1. Meems LM, Cannon MV, Mahmud H, Voors AA, van Gilst WH, Sillje HH, Ruifrok WP, de Boer RA. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012;132:282–289.
    1. Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004;1705:69–89.
    1. Mujumdar VS, Tyagi SC. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens. 1999;17:261–270.
    1. Murphy G, Segain JP, O'Shea M, Cockett M, Ioannou C, Lefebvre O, Chambon P, Basset P. The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. J Biol Chem. 1993;268:15435–15441.
    1. Nagase H. Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res. 1998;8:179–186.
    1. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–573.
    1. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, Allen C, Doughertly C, Gunter EW, Bowman BA. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr. 2002;76:187–192.
    1. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008;37:113–119.
    1. Norian JM, Malik M, Parker CY, Joseph D, Leppert PC, Segars JH, Catherino WH. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci. 2009;16:1153–1164.
    1. Ohara N. A putative role of versican in uterine leiomyomas. Clin Exp Obstet Gynecol. 2009;36:74–75.
    1. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem. 1997;272:2446–2451.
    1. Olson MW, Bernardo MM, Pietila M, Gervasi DC, Toth M, Kotra LP, Massova I, Mobashery S, Fridman R. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem. 2000;275:2661–2668.
    1. Ottino P, Taheri F, Bazan HE. Platelet-activating factor induces the gene expression of TIMP-1, -2, and PAI-1: imbalance between the gene expression of MMP-9 and TIMP-1 and -2. Exp Eye Res. 2002;74:393–402.
    1. Patterson ML, Atkinson SJ, Knauper V, Murphy G. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett. 2001;503:158–162.
    1. Polgar A, Falus A, Koo E, Ujfalussy I, Sesztak M, Szuts I, Konrad K, Hodinka L, Bene E, Meszaros G, et al. Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases. Rheumatology (Oxford) 2003;42:522–527.
    1. Rahman A, Hershey S, Ahmed S, Nibbelink K, Simpson RU. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol. 2007;103:416–419.
    1. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 1995;172:14–18.
    1. Sabry M, Halder SK, Allah AS, Roshdy E, Rajaratnam V, Al-Hendy A. Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study. Int J Womens Health. 2013;5:93–100.
    1. Sharan C, Halder SK, Thota C, Jaleel T, Nair S, Al-Hendy A. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011;95:247–253.
    1. Sintov AC, Berkovich L, Ben-Shabat S. Inhibition of cancer growth and induction of apoptosis by BGP-13 and BGP-15, new calcipotriene-derived vitamin D(3) analogs, in-vitro and in-vivo studies. Invest New Drugs. 2013;31:247–255.
    1. Sozen I, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril. 2002;78:1–12.
    1. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90:520–530.
    1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.
    1. Stewart EA, Friedman AJ, Peck K, Nowak RA. Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab. 1994;79:900–906.
    1. Tempfer H, Gehwolf R, Lehner C, Wagner A, Mtsariashvili M, Bauer HC, Resch H, Tauber M. Effects of crystalline glucocorticoid triamcinolone acetonide on cultered human supraspinatus tendon cells. Acta Orthop. 2009;80:357–362.
    1. Tetlow LC, Woolley DE. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion. Arthritis Res. 1999;1:63–70.
    1. Timms PM, Mannan N, Hitman GA, Noonan K, Mills PG, Syndercombe-Court D, Aganna E, Price CP, Boucher BJ. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95:787–796.
    1. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–839.
    1. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308:1589–1592.
    1. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988–1990. Obstet Gynecol. 1994;83:549–555.
    1. Wilson EA, Yang F, Rees ED. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues. Obstet Gynecol. 1980;55:20–24.
    1. Woessner JF., Jr The family of matrix metalloproteinases. Ann N Y Acad Sci. 1994;732:11–21.
    1. Wolanska M, Sobolewski K, Bankowski E, Jaworski S. Matrix metalloproteinases of human leiomyoma in various stages of tumor growth. Gynecol Obstet Invest. 2004;58:14–18.
    1. Zucker S, Lysik RM, Zarrabi MH, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993;53:140–146.

Source: PubMed

3
購読する